Jamie Harris
Analyst · Oppenheimer. Your question please
Thanks, Gene. We're pleased with our results for the quarter. We grew adjusted EPS by $0.15 to $0.49 per share, an increase of approximately 44%. In addition to the segment drivers, which I will review shortly, several below the line items had a modest impact on our net results. These include: first, higher corporate costs, primarily associated with the strategic investments and continuous improvement and other initiatives. Because of the accounting associated with the reclassification of our transformer business to discontinued operations, our results from continuing operations include approximately $1 million of stranded cost as the historical allocation to the transformer business is eliminated. This was only an accounting reclassification and had no effect on cash. Prospectively, once the sale of transformers is completed, we expect the TSA income to largely offset these calls throughout the 18 months. In addition, we will actively manage corporate cost to an appropriate level for both our business strategy and scale. Next, the $2.7 million revision to the reported insurance assets associated with potential legacy product liability claims. This expense had no in-period cash impact. We had – also had less interest expense due to lower average debt balances and the beginning of a new swap arrangement, which carried a lower effective interest rate and began in April of 2021. We had other non-operating income of $2.7 million associated with the proceeds of life insurance benefits. And last, we had a lower tax rate, which is driven by interest earned and the tax refund that is due to the company and the release of reserves related to statute expirations. Overall, our Q2 results reflect a backdrop of very strong demand in our run rate businesses. Some are seeing their strongest levels of end market demand in years, and we are carefully managing tight labor markets and supply chain constraints to meet customer needs. As we look forward, we see a strong backlog building in our project-based businesses, where deliveries to date have been slower to return to pre-pandemic levels despite strengthening customer interest and activity. We believe this sets us up well for growth into next year and beyond. A review of our adjusted results shows an overall strong quarter. Revenues increased 15.3%, driven by 9.6% organic growth and 6.1% from the ULC, Sensors & Software and Sealite acquisitions. The organic revenue increase was due to strong performances in both our HVAC and Detection & Measurement segments. Operating income of $25.5 million was modestly above Q2 2020 and includes the impact of the revision to the recorded insurance asset mentioned above. Excluding this change in estimate, operating income would be $28.2 million, a 16% increase from the prior year with a relatively flat margin of 9.5%. As a reminder, this is our first time reporting with updated segment structure. With the agreement to sell our transformer business, we have moved that business into discontinued operations and eliminated the Engineered Solutions segment, leaving HVAC and Detection & Measurement as our two reportable segments. Our HVAC segment now includes the result of our process cooling business, which historically has been part of Engineered Solutions. As a reminder, our other segment only includes the remaining activities of our South Africa project, which is substantially complete operationally. I will now review the details of our segment performance. Total HVAC segment revenues increased 12.2%, driven by 14.1% organic growth and a modest currency impact. These were partially offset by the impact of a contract settlement related to a legacy business, which had no impact on profit. Key sales were particularly strong and the primary driver of the organic increase. In the prior year period, heating product sales were negatively impacted by warmer than typical weather and the COVID-19 pandemic. Overall, cooling sales rose modestly with growth in the Asia Pacific region, where sales in the prior quarter were negatively impacted by the COVID-19 pandemic. Adjusted segment income increased by $5.8 million and rose 180 basis points due to higher volumes and continuous improvement initiatives, partially offset by higher input costs, including freight. We continue to be encouraged about the strength and demand we are seeing in heating and for the Americas and Asia Pacific region in our cooling business. While effectively managing labor and input constraints continues to be an area of focus, we feel good about our full year outlook and growth opportunities. In Detection & Measurement, revenues were up 20.7% year-over-year, including a modest organic increase and a 17.2% impact from the ULC, Sensors & Software and Sealite acquisitions. Overall, we are seeing significant year-over-year strength in shorter cycle products, while project-oriented shipments continue to face some delays despite strong customer interest and activity. Location and inspection had one of the strongest quarters on record, while our transportation business had lower revenue due to a large project delivery in the prior year that did not repeat. Adjusted segment income increased modestly. Segment margin decreased 290 basis points due to the mix effect of lower revenue from our project-based businesses. We believe this is largely due to timing as backlog has been building. As a reminder, our project businesses carry high contribution margins, so the timing of project revenue can have a noticeable impact on segment income and the related margins. Organically, Detection & Measurement segment bookings are up 17% from the prior year, while backlog is up 50% and has more than doubled when including the effect of acquisitions. We believe this positions us very well for growth in the next year and beyond. Turning now to our financial position at the end of the quarter. Our balance sheet remains strong. After purchasing ECS for approximately $38 million subsequent to quarter end, pro forma leverage was 1.8 times or up slightly from the last quarter. The leverage calculation includes the effect of potential contingent consideration that is not included in $38 million. Year-to-date, adjusted free cash flow was approximately $31 million, up significantly from prior year. For the full year, we anticipate solid cash generation with conversion of around 100%. We anticipate that after the close of the sale of transformers, we will repay the revolver borrowing and other short-term debt. While we would expect to keep our term loan in place for the time being, we anticipate having a significant amount of net cash on our balance sheet following the sale. Cash usage associated with South Africa was $6 million in the quarter, including the net effects of a dispute received by us and claims made on our bonds. Year-to-date cash associated with South Africa's positive $3 million, driven by the favorable dispute awards and the associated cash received. We feel good about positioning and dispute resolution process and continue to see favorable momentum. Overall, our strong balance sheet positions us well to pursue organic and inorganic growth initiatives. Moving to our guidance. We have updated our full year 2021 guidance to reflect the strength of our underlying businesses and the ECS acquisition, which we anticipate will add a few cents to EPS based on approximately four months of ownership. We now estimate adjusted earnings per share in the range of $2.25 to $2.45, up from prior guidance in the range of $2.17 to $2.37. At the midpoint, this reflects a growth of over 27% versus 2020 adjusted results, which have been recast for the movement of transformers to discontinued operations. As always, you will find more details on our guidance in the appendix to today's slides. With respect to the cadence of results for the remainder of the year, we are seeing strong backlog build in our project-oriented businesses with an anticipated Q3 delivery profile and overall segment results similar to the second quarter and significantly higher in the fourth quarter. I will now turn the call back to Gene.